Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1998, the company has made significant strides in developing innovative therapies, particularly in the fields of infectious diseases and rare genetic disorders. Achillion is renowned for its cutting-edge research and development, focusing on small molecule drugs that target specific viral infections and complement-mediated diseases.
With a strong emphasis on advancing treatments for hepatitis C and other viral infections, Achillion has positioned itself as a leader in the market. The company’s unique approach to drug development, combined with its commitment to scientific excellence, has led to notable achievements, including strategic partnerships and a robust pipeline of potential therapies. As it continues to expand its operational reach, Achillion Pharmaceuticals remains dedicated to improving patient outcomes through groundbreaking medical solutions.
+57 vs industry average
Achillion Pharmaceuticals, Inc.’s score of 95 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Achillion Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Achillion Pharmaceuticals, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Achillion Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Achillion Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from AstraZeneca PLC
Carbon Disclosure Project
Inherited from AstraZeneca PLCThe Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from AstraZeneca PLCClimate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project